What records are connected here?
- Evidence lanes
- 3
- Source years
- 7
- Drugs@FDA applications
- 2
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsInflammation and immune
Pegcetacoplan is made of two identical 15-amino-acid peptides joined to the ends of a polyethylene glycol (PEG) chain. It blocks complement protein C3, part of the immune system, and is the active ingredient in Empaveli.1,2 Empaveli is approved for paroxysmal nocturnal hemoglobinuria (PNH) in adults and for two kidney diseases, C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, in patients 12 and older.1 The label carries a boxed warning that it raises the risk of serious, life-threatening infections with encapsulated bacteria such as meningococcus and pneumococcus.1
| What it is | Two identical synthetic 15-amino-acid peptides attached to a 40-kilodalton PEG molecule, which bind complement C3 and C3b, according to the Empaveli label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Empaveli, NDA 215014, approved May 14, 2021, and a second pegcetacoplan product, Syfovre, NDA 217171, approved February 17, 2023. The Empaveli label has a boxed warning about serious infections.1,2,3 |
| Human evidence | Randomized Phase 3 trials described in the label, including an 80-patient PNH trial against eculizumab and a 124-patient placebo-controlled kidney trial.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Pegcetacoplan is a symmetrical molecule of two identical 15-amino-acid peptides, each containing a modified tryptophan, bound to either end of a linear 40-kilodalton PEG chain, according to the label.1
In the United States it is the active ingredient of Empaveli, approved under NDA 215014, and of Syfovre, approved under NDA 217171, according to Drugs@FDA.2,3
The label states that pegcetacoplan binds complement protein C3 and its fragment C3b, controlling an early step of the complement cascade. In PNH this limits red blood cell destruction both inside and outside blood vessels.1
In C3 glomerulopathy and IC-MPGN, the label states that blocking C3 activation reduces the deposits of C3 fragments in the kidney’s filtering units.1
In Study APL2-302, 80 adults with PNH who still had low hemoglobin on eculizumab were randomized to Empaveli or to continue eculizumab. The label states that Empaveli was superior for the change in hemoglobin at week 16.1
In Study APL2-C3G-310, a placebo-controlled trial in 124 patients with C3 glomerulopathy or primary IC-MPGN, protein in the urine fell by 68% relative to placebo after 26 weeks, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Empaveli, application NDA 215014, with an original approval date of May 14, 2021, and Syfovre, application NDA 217171, approved February 17, 2023.2,3
The Empaveli label cited here (DailyMed SPL version 14, published August 25, 2026) states that it is indicated for adults with PNH and for patients 12 and older with C3 glomerulopathy or primary IC-MPGN, to reduce protein in the urine and the loss of kidney function.1
The label carries a boxed warning that Empaveli increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type B.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Pegcetacoplan is not among them.4,5
Its safety and effectiveness in recurrent IC-MPGN after a kidney transplant, which the label states have not been established.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Pegcetacoplan: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Pegcetacoplan are a bounded selection, not every registration or paper about Pegcetacoplan. For the years before Pegcetacoplan was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Pegcetacoplan as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Pegcetacoplan in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Empaveli for PNH and two complement-driven kidney diseases. Randomized trials described in the label support its approved uses, including a trial against eculizumab in PNH. The label has a boxed warning about serious infections with encapsulated bacteria.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Empaveli for PNH and two complement-driven kidney diseases. Randomized trials described in the label support its approved uses, including a trial against eculizumab in PNH. The label has a boxed warning about serious infections with encapsulated bacteria.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 13, 2026
Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN.↗Source date November 13, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT06722157↗Source date November 12, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT03531255↗Source date November 10, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
21 of 23 selected trial records include at least one phase value; 23 of 23 include a status value in the retained structured contract.
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT02264639 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT02461771 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT02503332 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span October 6, 2020 to November 13, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 43024395 in Journal of the American Society of Nephrology : JASN as Journal Article, with publication-date metadata of 2026-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06722157 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03531255 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗
Literature metadata
PubMed lists PMID 42998772 in Survey of ophthalmology as Journal Article, Review, with publication-date metadata of 2026-11-07 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07898774 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗
Literature metadata
PubMed lists PMID 42972953 in Turkish journal of haematology : official journal of Turkish Society of Haematology as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42930807 in Journal of personalized medicine as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42898424 in Kidney international reports as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42800616 in Kidney international as Case Reports, Journal Article, with publication-date metadata of 2026-09-26 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39497616 in CPT: pharmacometrics & systems pharmacology as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-11-05 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07746895 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05776472 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026